SG169348A1 - Generation of heavy-chain only antibodies in transgenic animals - Google Patents
Generation of heavy-chain only antibodies in transgenic animalsInfo
- Publication number
- SG169348A1 SG169348A1 SG201100537-8A SG2011005378A SG169348A1 SG 169348 A1 SG169348 A1 SG 169348A1 SG 2011005378 A SG2011005378 A SG 2011005378A SG 169348 A1 SG169348 A1 SG 169348A1
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- generation
- heavy
- chain
- transgenic animals
- Prior art date
Links
- 230000009261 transgenic effect Effects 0.000 title abstract 3
- 241001465754 Metazoa Species 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1285—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0601511.9A GB0601511D0 (en) | 2006-01-25 | 2006-01-25 | Binding Molecules 2 |
GBGB0618345.3A GB0618345D0 (en) | 2006-09-18 | 2006-09-18 | Binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
SG169348A1 true SG169348A1 (en) | 2011-03-30 |
Family
ID=38437750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201100537-8A SG169348A1 (en) | 2006-01-25 | 2007-01-25 | Generation of heavy-chain only antibodies in transgenic animals |
Country Status (11)
Country | Link |
---|---|
US (3) | US20090307787A1 (ko) |
EP (1) | EP1991580A2 (ko) |
JP (1) | JP5184374B2 (ko) |
KR (1) | KR101481843B1 (ko) |
AU (1) | AU2007219159B8 (ko) |
BR (1) | BRPI0706750A2 (ko) |
CA (1) | CA2638117A1 (ko) |
RU (1) | RU2435784C2 (ko) |
SG (1) | SG169348A1 (ko) |
TW (1) | TWI404727B (ko) |
WO (1) | WO2007096779A2 (ko) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
RU2398882C2 (ru) * | 2004-07-22 | 2010-09-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ |
BRPI0706750A2 (pt) * | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
WO2008151081A1 (en) | 2007-06-01 | 2008-12-11 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
KR20110020860A (ko) | 2008-05-23 | 2011-03-03 | 알리바 바이오파마수티컬스, 아이엔씨. | 유전자 삽입동물에서 단일 vl 도메인 항체를 생산하는 방법 |
US20100122358A1 (en) * | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
CN112680475A (zh) * | 2008-12-18 | 2021-04-20 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
SI2509409T1 (sl) | 2009-12-10 | 2016-12-30 | Regeneron Pharmaceuticals, Inc. | Miši, ki tvorijo protitelesa težke verige |
ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US9516868B2 (en) | 2010-08-02 | 2016-12-13 | Regeneron Pharmaceuticals, Inc. | Mice that make VL binding proteins |
PL3572517T3 (pl) | 2011-08-05 | 2021-10-04 | Regeneron Pharmaceuticals, Inc. | Myszy z humanizowanym uniwersalnym łańcuchem lekkim |
JP5813880B2 (ja) | 2011-09-19 | 2015-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
RU2664181C2 (ru) | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
NZ717848A (en) | 2012-06-12 | 2019-03-29 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102239125B1 (ko) | 2012-12-14 | 2021-04-12 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 인간 이디오타입을 갖는 설치류 항체를 인코딩하는 폴리뉴클레오티드 및 이를 포함하는 동물 |
PT2840892T (pt) | 2013-02-20 | 2018-07-20 | Regeneron Pharma | Animais não humanos com sequências da cadeia pesada da imunoglobulina modificada |
US9980470B2 (en) | 2013-03-14 | 2018-05-29 | Erasmus University Medical Center | Antibody production |
WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
KR20210088756A (ko) | 2014-03-21 | 2021-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
ES2828694T3 (es) | 2015-07-29 | 2021-05-27 | Allergan Inc | Anticuerpos sólo de cadena pesada frente a ANG-2 |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
US10308711B2 (en) | 2015-08-14 | 2019-06-04 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
AU2016332900C1 (en) | 2015-09-29 | 2024-02-01 | Amgen Inc. | ASGR inhibitors |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
CN110662421B (zh) | 2017-01-19 | 2023-03-24 | 欧莫诺艾比公司 | 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体 |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
AU2018396970A1 (en) | 2017-12-28 | 2020-08-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
JP7383617B2 (ja) | 2017-12-28 | 2023-11-20 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Pd-l1に対する抗体及びそのバリアント |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
CN117964751A (zh) * | 2018-03-13 | 2024-05-03 | 斯米维特公司 | 与破伤风神经毒素结合的单域抗体 |
CN108486125B (zh) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在制备人源单域抗体中的应用 |
EP3774917A4 (en) | 2018-03-30 | 2022-01-19 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF |
US11987629B2 (en) | 2018-06-01 | 2024-05-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
US20220275059A1 (en) | 2019-02-20 | 2022-09-01 | Harbour Antibodies Bv | Antibodies |
MX2021015045A (es) | 2019-06-07 | 2022-03-17 | Amgen Inc | Construcciones de unión biespecíficas. |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
EP4097144A4 (en) * | 2020-01-28 | 2024-02-28 | Univ Southern California | GENOME ENGINEERING OF THE HUMAN IMMUNOLOBULIN LOCUS FOR EXPRESSING RECOMBINANT BINDING DOMAIN MOLECULES |
CN115066440A (zh) | 2020-02-28 | 2022-09-16 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
JP2023516941A (ja) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗cd137コンストラクト、多重特異性抗体及びその使用 |
GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
AU2021283345A1 (en) | 2020-06-02 | 2023-02-02 | Dynamicure Biotechnology Llc | Anti-CD93 constructs and uses thereof |
US20230203198A1 (en) | 2020-06-04 | 2023-06-29 | Amgen Inc. | Bispecific binding constructs |
JP2023530919A (ja) | 2020-06-17 | 2023-07-20 | ヤンセン バイオテツク,インコーポレーテツド | 多能性幹細胞の製造のための材料及び方法 |
US20230303698A1 (en) | 2020-06-30 | 2023-09-28 | Harbour Biomed (Shanghai) Co., Ltd | Multispecific binding protein of immune cell engager, preparation therefor and application thereof |
EP4154910A1 (en) | 2020-06-30 | 2023-03-29 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
AU2021315665A1 (en) | 2020-07-29 | 2023-03-16 | Dynamicure Biotechnology Llc | Anti-CD93 constructs and uses thereof |
US11484027B2 (en) | 2020-10-29 | 2022-11-01 | Industrial Polymers and Chemicals, Inc. | Air filter with pathogen monitoring and inactivation |
GB202017555D0 (en) | 2020-11-06 | 2020-12-23 | Harbour Antibodies Bv | Antibody-conjugated nanoparticles |
CN116783217A (zh) | 2020-12-03 | 2023-09-19 | 安进公司 | 具有多个结合结构域的免疫球蛋白构建体 |
EP4258865A1 (en) | 2020-12-09 | 2023-10-18 | Trianni, Inc. | Heavy chain-only antibodies |
BR112023016713A2 (pt) | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
KR20220118962A (ko) | 2021-02-19 | 2022-08-26 | (주)샤페론 | Pd-l1에 대한 단일 도메인 항체 및 이의 용도 |
EP4296284A1 (en) | 2021-02-19 | 2023-12-27 | SHAPERON Inc. | Bispecific single domain antibody to pd-l1 and cd47 and use thereof |
WO2022187863A1 (en) | 2021-03-05 | 2022-09-09 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
EP4314049A1 (en) | 2021-03-25 | 2024-02-07 | Dynamicure Biotechnology LLC | Anti-igfbp7 constructs and uses thereof |
EP4355785A1 (en) | 2021-06-17 | 2024-04-24 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
WO2024018426A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4633464A (en) * | 1983-08-08 | 1986-12-30 | At&T Bell Laboratories | Control signalling arrangement for a digital transmission system |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US20050287630A1 (en) * | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
AU8470301A (en) * | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
GB0228210D0 (en) * | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
GB0401882D0 (en) | 2004-01-28 | 2004-03-03 | Inpharmatica Ltd | Protein |
RU2398882C2 (ru) * | 2004-07-22 | 2010-09-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
-
2007
- 2007-01-25 BR BRPI0706750-0A patent/BRPI0706750A2/pt not_active IP Right Cessation
- 2007-01-25 KR KR1020087020712A patent/KR101481843B1/ko active IP Right Grant
- 2007-01-25 EP EP07734772A patent/EP1991580A2/en not_active Withdrawn
- 2007-01-25 TW TW096102903A patent/TWI404727B/zh active
- 2007-01-25 US US12/161,981 patent/US20090307787A1/en not_active Abandoned
- 2007-01-25 AU AU2007219159A patent/AU2007219159B8/en active Active
- 2007-01-25 JP JP2008551908A patent/JP5184374B2/ja active Active
- 2007-01-25 RU RU2008134517/10A patent/RU2435784C2/ru active
- 2007-01-25 CA CA002638117A patent/CA2638117A1/en not_active Abandoned
- 2007-01-25 SG SG201100537-8A patent/SG169348A1/en unknown
- 2007-01-25 WO PCT/IB2007/001491 patent/WO2007096779A2/en active Application Filing
-
2015
- 2015-12-08 US US14/962,335 patent/US10638735B2/en active Active
-
2020
- 2020-04-15 US US16/848,943 patent/US20200267951A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1991580A2 (en) | 2008-11-19 |
TWI404727B (zh) | 2013-08-11 |
JP5184374B2 (ja) | 2013-04-17 |
TW200808825A (en) | 2008-02-16 |
KR101481843B1 (ko) | 2015-01-12 |
US20160295843A1 (en) | 2016-10-13 |
WO2007096779A3 (en) | 2008-06-26 |
JP2009524641A (ja) | 2009-07-02 |
KR20090013748A (ko) | 2009-02-05 |
BRPI0706750A2 (pt) | 2011-04-05 |
CA2638117A1 (en) | 2007-08-30 |
RU2008134517A (ru) | 2010-02-27 |
US20200267951A1 (en) | 2020-08-27 |
US20090307787A1 (en) | 2009-12-10 |
US10638735B2 (en) | 2020-05-05 |
AU2007219159B8 (en) | 2012-06-28 |
RU2435784C2 (ru) | 2011-12-10 |
AU2007219159B2 (en) | 2012-06-14 |
WO2007096779A2 (en) | 2007-08-30 |
AU2007219159A1 (en) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG169348A1 (en) | Generation of heavy-chain only antibodies in transgenic animals | |
GB201208708D0 (en) | Antibodies | |
HRP20160158T4 (hr) | Topiva protutijela koja sadrže samo teške lance | |
WO2009157771A3 (en) | Antibody producing non-human mammals | |
WO2009155726A3 (en) | Humanization of rabbit antibodies using a universal antibody framework | |
MX2011007660A (es) | Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos. | |
WO2013061098A3 (en) | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes | |
WO2012148873A3 (en) | Non-human animals expressing antibodies having a common light chain | |
WO2009097006A3 (en) | Hco32 and hco27 and related examples | |
WO2009152529A3 (en) | Programming and reprogramming of cells | |
EP2162469A4 (en) | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES | |
MY172718A (en) | Humanized universal light chain mice | |
WO2009013620A3 (en) | Homologous recombination | |
HK1200269A1 (en) | Method for generating an non-human animal homozygous for a genetic modification | |
WO2009143472A3 (en) | Method of generating single vl domain antibodies in transgenic animals | |
MX2009010282A (es) | Anticuerpos biespecificos y metodos para su produccion. | |
WO2010115589A8 (en) | Trivalent, bispecific antibodies | |
NO20063767L (no) | Antistoffer mot clostridium difficile toksiner og anvendelser derav | |
GB0110029D0 (en) | Transgenic animal | |
IL187308A0 (en) | Method of producing antibodies with modified fucosylation level | |
WO2008035216A3 (en) | Generation of heavy-chain only antibodies in transgenic animals | |
IL192207A0 (en) | Chimeric and humanised anti-human il -13 antibodies | |
MX2009004170A (es) | Materiales y metodos para inmunoglicoproteinas mejoradas. | |
ZA201004046B (en) | Anti-human il-21 monoclonal antibodies | |
WO2010121093A3 (en) | Humanized antibody compositions and methods for binding lysophosphatidic acid |